Health Technology Assessment (HTA) for Medical Devices: Complete Guide to Market Access and Reimbursement

What Is Health Technology Assessment (HTA)?

Health Technology Assessment (HTA) is the systematic evaluation of the properties, effects, and impacts of health technologies and interventions. It is the process that determines whether a medical device (or drug, diagnostic, or digital health tool) provides sufficient clinical and economic value to justify its cost — and therefore whether it will be reimbursed or covered by a healthcare system.

For medical device manufacturers, HTA is the gateway between regulatory approval and actual patient access. A device may have CE marking in Europe or FDA clearance in the US, but if it fails to demonstrate value through HTA, it will not be purchased by hospitals, covered by insurance, or reimbursed by national health systems. Regulatory approval gives you the right to market a device; HTA determines whether anyone will pay for it.

HTA evaluates technologies across multiple dimensions:

How HTA Differs from Regulatory Approval

The EU HTA Regulation: A New Era (2025-2026)

The EU HTA Regulation (Regulation 2021/2282) represents the most significant change to European health technology assessment in decades. It mandates joint clinical assessments (JCAs) at the EU level, replacing the previous system where each Member State conducted its own assessment independently.

What Changed and When

Medical Devices Enter Scope in 2026

The HTACG's (HTA Coordination Group) 2026 Annual Work Programme identifies approximately 5 joint clinical assessments of selected high-risk medical devices to be initiated in 2026, with the first expected to begin in June 2026. The Emerging Health Technologies report identifies 15 medical device categories potentially eligible for JCAs, including:

• Implantable prosthetics
• Active implantable devices
• Cardiocirculatory devices

This is the first year that high-risk medical devices meaningfully enter the EU-level HTA assessment process. The implementing act for medical device JCAs has been published, completing the legal framework for device assessment at the EU level.

Which Medical Devices Are Eligible for JCA?

The HTACG's Emerging Health Technologies report identifies 15 medical device categories potentially eligible for JCAs in 2026. These include Class IIb/III medical devices and Class D IVDs across therapeutic areas including:

• Implantable prosthetics (orthopedic, cardiovascular)
• Active implantable devices (pacemakers, neurostimulators)
• Cardiocirculatory devices (heart valves, stents, ventricular assist devices)
• Advanced surgical robotics
• High-risk diagnostic imaging systems
• Innovative wound care technologies

The selection criteria prioritize devices with significant clinical impact, high cost, and potential for cross-border variation in access. This represents a fundamental shift: medical device manufacturers will need to prepare evidence packages that satisfy both the EU MDR clinical evaluation requirements AND the HTA clinical and economic evidence requirements simultaneously.

Joint Clinical Assessment (JCA) Process for Medical Devices

The JCA process evaluates the clinical evidence for a health technology at the EU level. The assessment is conducted jointly by Member State assessors, and the resulting report is then used by individual Member States to inform their national pricing and reimbursement decisions.

Key facts about the JCA process for devices in 2026:

• Scope: Approximately 5 high-risk medical devices selected by HTACG
• Timeline: Assessments expected to take 150-270 days from start to final report
• Assessors: Two Member States serve as assessor and co-assessor for each JCA
• Output: A joint clinical assessment report that feeds into national HTA processes
• Cost: Joint scientific consultations (JSCs) are offered free of charge to health technology developers in 2026

Joint Scientific Consultations (JSCs)

Before submitting for a JCA, manufacturers can request a Joint Scientific Consultation to get early feedback on their evidence development strategy. In 2026:

• 8-12 JSCs planned for medicines
• 2-5 JSCs planned for medical devices
• No fees for JSCs in 2026
• Request periods: January 7-February 4, April 1-29, June 3-July 1, September 23-October 21

JSCs are a critical opportunity for medical device manufacturers to ensure their evidence generation plans will meet JCA requirements before investing in costly clinical studies.

Major HTA Bodies and Their Frameworks

United Kingdom: NICE

The National Institute for Health and Care Excellence (NICE) is the most established HTA body for medical devices. NICE develops HealthTech Guidance (HTG) to evaluate diagnostics, medical devices, and digital technologies including AI.

NICE assessment process:

• Cost-effectiveness threshold: Typically £20,000-£30,000 per quality-adjusted life year (QALY) gained
• Evidence standards: NICE requires robust clinical evidence, preferably from randomized controlled trials
• Patient engagement: NICE actively solicits patient and carer input
• Appeals process: Manufacturers can appeal negative decisions

Key 2026 update: In March 2026, MHRA and NICE launched an aligned process for medicines that synchronizes regulatory licensing with HTA evaluation, potentially accelerating patient access by 3-6 months. While medical devices are not included in this initial rollout, it signals a trend toward closer regulatory-HTA alignment.

Germany: G-BA and IQWIG

Germany's Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) makes coverage decisions, with IQWIG (Institute for Quality and Efficiency in Health Care) conducting assessments.

• Evidence hierarchy: Strong preference for randomized controlled trials
• Free pricing for new devices: Manufacturers set prices for the first year while G-BA evaluates
• Formal assessment: After evaluation, G-BA determines if the device will be included in standard reimbursement
• High evidentiary bar: Germany is known for requiring the most rigorous clinical evidence in Europe

France: HAS

The French National Authority for Health (Haute Autorité de Santé, HAS) evaluates medical devices for reimbursement:

• Service Attendu (SA): Assessment of clinical benefit on a scale from sufficient to insufficient
• Amélioration du Service Attendu (ASA): Assessment of improvement over existing alternatives (I to V)
• Pricing: Negotiated with the Economic Committee for Health Products (CEPS) based on ASA rating
• Innovation premium: Devices with ASA I or II may receive premium pricing

Italy: National HTA Program

Italy launched the operational phase of its 2026-2028 National HTA Program for Medical Devices, coordinated by AGENAS with approximately €13 million in funding. Regional HTAs are also conducted (Tuscany released rapid HTAs of medical devices in January and March 2026). Italy uses a combination of national and regional assessments.

Other European HTA Bodies

HTA Evidence Requirements for Medical Devices

Clinical Evidence

Medical device clinical evidence for HTA differs from regulatory clinical evidence in important ways:

Economic Evidence

Economic modeling is central to HTA submissions. The most common approaches:

Key economic modeling inputs:

• Clinical effectiveness data from trials or real-world evidence
• Resource use and cost data (procedure costs, hospital stays, follow-up care)
• Utility values (quality of life weights) for QALY calculations
• Epidemiological data (disease prevalence, incidence)
• Device cost (including acquisition, implantation, and maintenance)

Patient and Real-World Evidence

HTA bodies increasingly expect evidence beyond traditional clinical trials:

• Patient-reported outcomes (PROs) — Direct measures of patient health status, quality of life, and functional outcomes
• Real-world evidence (RWE) — Data from clinical practice (registries, electronic health records, claims databases)
• Patient preference studies — Quantitative assessments of patient values and trade-offs

The FDA's 2026 guidance on Voluntary Patient Preference Information (PPI) encourages collection of patient preference data across the total product lifecycle, aligning with EU MDR/IVDR PMCF/PMPF principles.

HTA Strategy for Medical Device Manufacturers

Start Early: Evidence Planning from Day One

The single most important strategic advice for HTA success: begin evidence planning before your clinical trial design is finalized. HTA evidence requirements should inform clinical trial design, not the other way around.

Recommended timeline:

Build an HTA Evidence Package

For each target market, prepare:

1. Clinical evidence dossier — Systematic review, clinical study reports, meta-analyses
2. Economic model — Cost-effectiveness or cost-utility analysis adapted to the local health system
3. Budget impact analysis — Projected cost to the payer over 3-5 years
4. Patient evidence — Patient-reported outcomes, patient preference studies
5. Organizational impact assessment — How the device changes clinical pathways
6. Comparator analysis — Clinical and economic comparison to current standard of care

Engage with HTA Bodies Early

Most HTA bodies offer mechanisms for early engagement:

Challenges Specific to Medical Device HTA

Medical devices face HTA challenges that differ from pharmaceuticals:

1. Iterative Innovation

Unlike drugs, medical devices evolve incrementally. A new version of an implant or monitoring system may offer marginal improvements over the previous generation. HTA bodies designed for pharmaceutical "step-change" innovations struggle to evaluate incremental improvements.

2. Learning Curve and Operator Dependence

Device performance often depends on operator skill and experience. A surgical device used by an experienced surgeon will outperform the same device used by a novice. This makes it difficult to generalize clinical trial results.

3. Short Product Lifecycles

Medical devices have shorter lifecycles than drugs (typically 18-36 months before the next generation). By the time an HTA assessment is completed, the device may have been superseded. This creates tension between the need for rigorous assessment and the pace of innovation.

4. Limited RCT Evidence

Randomized controlled trials are more difficult to conduct for medical devices than drugs (blinding is often impossible, sham procedures are ethically challenging, and the device may evolve during the trial). HTA bodies must accept alternative evidence, but their frameworks are often drug-centric.

5. Pricing and Reimbursement Fragmentation

Unlike drugs (which have national pricing in most markets), medical device pricing and reimbursement is often fragmented — different hospitals may pay different prices, and reimbursement may vary by region, indication, or patient population. This complicates HTA analysis.

Global HTA Landscape Beyond Europe

Frequently Asked Questions

Does my device need an HTA assessment in every EU country?

With the EU HTA Regulation, the clinical assessment component (JCA) is conducted once at the EU level. However, the economic evaluation, pricing negotiation, and coverage decision remain at the national level. You will still need country-specific economic models and pricing strategies, but the clinical evidence review should be streamlined.

When should I start HTA planning for my medical device?

Ideally, during the clinical trial design phase. HTA evidence requirements should inform what endpoints you measure, what comparators you include, and how long you follow patients. Retrofitting HTA evidence collection after the trial is complete is always more expensive and often insufficient.

What is a QALY and why does it matter?

A Quality-Adjusted Life Year (QALY) is a measure of health outcome that combines both length and quality of life. One QALY equals one year in perfect health. HTA bodies use cost per QALY gained to compare the value of different health technologies. In the UK, NICE typically considers interventions costing £20,000-£30,000 per QALY gained to be cost-effective.

How does the EU HTA Regulation affect my EU MDR technical file?

The EU HTA Regulation is separate from the EU MDR, but they are interconnected. Your clinical evaluation report (CER) under the EU MDR can serve as a starting point for the clinical evidence in your HTA submission. However, HTA requires additional evidence (economic modeling, patient outcomes, comparator analysis) that goes beyond what is needed for the EU MDR.

What happens if my device receives a negative HTA assessment?

A negative HTA assessment does not prevent you from selling the device — but it means the device will not be reimbursed or covered by the health system in that market. In practice, this severely limits market access because most patients cannot afford to pay out-of-pocket. Most HTA bodies offer an appeals or reconsideration process, and manufacturers can submit additional evidence to support a revised assessment.